description
In addition to the highly prevalent and activating V600E BRAF mutations, numerous moderately activating and less common mutations have also been identified in human cancers (Forbes et al, 2015). Unlike the case for their highly activating counterparts, signaling through these mutant versions of BRAF depends both upon RAS binding and RAF dimerization (Wan et al, 2004; Freeman et al, 2013; Roring et al, 2012; reviewed in Lito et al, 2013; Lavoie and Therrien, 2015

external resources
NCBI:1457784
REACTOME:R-HSA-6802946
PUBMED:25907612
PUBMED:15035987
PUBMED:24202393
PUBMED:22510884
PUBMED:25355519
PUBMED:23352452

genes
ARAF , ARRB1 , ARRB2 , BRAF , CSK , FGA , FGB , FGG , FN1 , HRAS , ITGA2B , ITGB3 , JAK2 , KRAS , MARK3 , MAP3K11 , NRAS , PEBP1 , PHB , MAPK1 , MAPK3 , MAP2K1 , MAP2K2 , RAF1 , RAP1A , RAP1B , SRC , TLN1 , VCL , VWF , YWHAB , BRAP , IQGAP1 , KSR1 , CNKSR1 , CNKSR2 , APBB1IP , KSR2 ,